Literature DB >> 31404442

A novel rat model of foreign body osteomyelitis for evaluation of antimicrobial efficacy.

Cassandra L Brinkman1, Suzannah M Schmidt-Malan1, Melissa J Karau1, Robin Patel1,2.   

Abstract

The most common organism-type causing orthopedic foreign body infection is the staphylococci, of which Staphylococcus aureus and Staphylococcus epidermidis are especially common. These organisms form biofilms on orthopedic foreign body surfaces, rendering such infections challenging and time consuming to treat. Our group evaluates novel therapeutics for orthopedic foreign body infection in animal models. A current limitation of most animal models is that that they only allow for the removal of one sample per animal, at the time of sacrifice. Herein, we describe a novel rat model of foreign body osteomyelitis that allows removal of foreign bodies at different time points, from the same infected animal. We demonstrate that this model can be used for both S. aureus and S. epidermidis orthopedic foreign body infection, with 3.56, 3.60 and 5.51 log10 cfu/cm2 S. aureus recovered at four, five and six weeks, respectively, after infection, and 2.08, 2.17 and 2.62 log10 cfu/cm2 S. epidermidis recovered at four, five and six weeks, respectively, after infection We evaluated the model with S. aureus infection treated with rifampin 25 mg/kg twice daily for 21 days. Using quantitative cultures, we were no longer able to detect bacteria as of the 14th day of treatment with bacteria becoming detectable again 7 days following die discontinuation of rifampin a period. This novel model allows monitoring of evolution of infection at the infection site in the same animal.

Entities:  

Keywords:  Novel model; antimicrobial efficacy; foreign-body osteomyelitis; rifampin

Year:  2019        PMID: 31404442      PMCID: PMC6688763          DOI: 10.20454/jeaas.2019.1555

Source DB:  PubMed          Journal:  J Exp Appl Anim Sci        ISSN: 2314-5692


  10 in total

Review 1.  Prosthetic-joint infections.

Authors:  Werner Zimmerli; Andrej Trampuz; Peter E Ochsner
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

Review 2.  Infection and musculoskeletal conditions: Prosthetic-joint-associated infections.

Authors:  Werner Zimmerli
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-12       Impact factor: 4.098

3.  Impact of the economic downturn on total joint replacement demand in the United States: updated projections to 2021.

Authors:  Steven M Kurtz; Kevin L Ong; Edmund Lau; Kevin J Bozic
Journal:  J Bone Joint Surg Am       Date:  2014-04-16       Impact factor: 5.284

4.  Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group.

Authors:  W Zimmerli; A F Widmer; M Blatter; R Frei; P E Ochsner
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

5.  Rifampin-Based Combination Therapy Is Active in Foreign-Body Osteomyelitis after Prior Rifampin Monotherapy.

Authors:  Cassandra L Brinkman; Suzannah M Schmidt-Malan; Jayawant N Mandrekar; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

6.  Causes and Implications of the Disappearance of Rifampin Resistance in a Rat Model of Methicillin-Resistant Staphylococcus aureus Foreign Body Osteomyelitis.

Authors:  Cassandra L Brinkman; Harmony L Tyner; Suzannah M Schmidt-Malan; Jayawant N Mandrekar; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

7.  Comparative activities of vancomycin, tigecycline and rifampin in a rat model of methicillin-resistant Staphylococcus aureus osteomyelitis.

Authors:  Paschalis Vergidis; Suzannah M Schmidt-Malan; Jayawant N Mandrekar; James M Steckelberg; Robin Patel
Journal:  J Infect       Date:  2015-01-07       Impact factor: 6.072

Review 8.  Prosthetic joint infections: microbiology, diagnosis, management and prevention.

Authors:  Silvano Esposito; Sebastiano Leone
Journal:  Int J Antimicrob Agents       Date:  2008-07-09       Impact factor: 5.283

9.  Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus.

Authors:  H Aubry-Damon; C J Soussy; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

Review 10.  Prosthetic joint infection.

Authors:  Aaron J Tande; Robin Patel
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

  10 in total
  1 in total

1.  Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis.

Authors:  Melissa J Karau; Suzannah M Schmidt-Malan; Scott A Cunningham; Jayawant N Mandrekar; Bobbi S Pritt; Tiffany R Keepers; Alisa W Serio; Surya Chitra; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2021-11-01       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.